Business
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
On the heels of Longeveron’s recent announcement showing Lomecel-B significantly increased walking distance in older, frail subjects, Longeveron intends to
About this update from Longeveron Inc.
[{"type":"text","content":"On the heels of Longeveron’s recent announcement showing Lomecel-B significantly increased walking distance in older, frail subjects, Longeveron intends to implement Kinesiometrics new digital data-driven solution for capturing activity levels, quality of life, and clinical outcomes\nMIAMI, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or \"Company\"), a clinical stage biotechnology company developing its proprietary product, Lomecel-B, and other cellular therapies for chronic aging-related and life-threatening conditions, has entered into an agreement with Kinesiometrics Inc., (“Kinesiometrics”) to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality of life in Longeveron’s clinical studies. The data is accessible to Longeveron and recipients of Lomecel-B via an Application downloadable on the subjects’ mobile phones. Longeveron recently announced the results of a Phase 2b Aging Frailty study, which showed that frail subjects (average age for study was 75.2 years) with impaired mobility could walk nearly 50 meters further 180 days after a single intravenous infusion of Lomecel-B (200 million Lomecel-B group; p=0.0065). This increase was durable, persisting through 270 days (200 million Lomecel-B group change from baseline 47.9 meters; p=0.0115, and p","length":1766,"tagName":"div"}]